| P50 | author | Thunyarat Anothaisintawee | Q89539887 |
| P2093 | author name string | Kittiphon Nagaviroj | |
| | Anon Sathornviriyapong | |
| P2860 | cites work | Opioid use in last week of life and implications for end-of-life decision-making | Q44332967 |
| | Opioid use and survival at the end of life: a survey of a hospice population. | Q44333145 |
| | Increasing opioid therapy and survival in a hospice | Q44337745 |
| | Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. | Q44345808 |
| | Trends in the use of opioids at the end of life and the expected effects on hastening death | Q44666408 |
| | Thoughts of self-harm and depression as prognostic factors in palliative care patients | Q48256433 |
| | Opioids have no negative effect on the survival time of patients with advanced lung cancer in an acute care hospital. | Q51669750 |
| | Identifying attitudinal barriers to family management of cancer pain in palliative care in Taiwan | Q73543820 |
| | Opioids, survival, and advanced cancer in the hospice setting | Q83296134 |
| | Reliability and validity of the Thai translation (Thai PPS Adult Suandok) of the Palliative Performance Scale (PPSv2) | Q85084630 |
| | Value of the Palliative Performance Scale in the prognostication of advanced cancer patients in a tertiary care setting | Q86937922 |
| | [Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients] | Q87256818 |
| | The survival time of terminal cancer patients: prediction based on clinical parameters and simple prognostic scores | Q87872221 |
| | Cancer-Related Pain Management and the Optimal Use of Opioids | Q26784010 |
| | The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer | Q28541351 |
| | A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 |
| | Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease | Q30517901 |
| | An alternative algorithm for dosing transdermal fentanyl for cancer-related pain | Q33942797 |
| | Effects of high dose opioids and sedatives on survival in terminally ill cancer patients | Q33943205 |
| | Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer | Q33951506 |
| | Effects of opioids and sedatives on survival in an Australian inpatient palliative care population. | Q34443651 |
| | Opioid switching in cancer pain: From the beginning to nowadays | Q34510628 |
| | The use of opioids and sedatives at the end of life | Q35121721 |
| | Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer | Q35551918 |
| | Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. | Q37590738 |
| | Opioid use amongst cancer patients at the end of life | Q37808366 |
| | Symptom patterns of patients with head and neck cancer in a palliative care unit | Q37854054 |
| | Starting step III opioids for moderate to severe pain in cancer patients: dose titration: a systematic review | Q37894989 |
| | Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review | Q37894998 |
| | A systematic review of the influence of opioids on advanced cancer patient survival | Q38154458 |
| | Opioids prescription for symptoms relief and the impact on respiratory function: updated evidence. | Q38260558 |
| | The use of opioids at the end-of-life and the survival of Egyptian palliative care patients with advanced cancer. | Q38405145 |
| | The mu opioid receptor: A new target for cancer therapy? | Q38515846 |
| | Is regular systemic opioid analgesia associated with shorter survival in adult patients with cancer? A systematic literature review | Q38553484 |
| | Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review | Q38714549 |
| | Palliative performance scale and survival among outpatients with advanced cancer | Q39127993 |
| | Preferences of caregivers and patients regarding opioid analgesic use in terminal care | Q39199449 |
| | Patterns of high-dose morphine use in a home-care hospice service: should we be afraid of it? | Q39376077 |
| | Attitudes toward opioids for refractory dyspnea in COPD among Dutch chest physicians | Q41443211 |
| | Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study | Q41929905 |
| | Family perspectives on end-of-life care at the last place of care | Q42616720 |
| | Opioid use at the end of life and survival in a Hospital at Home unit | Q42924062 |
| | Independent predictors of survival in patients with incurable malignant gastric outlet obstruction: a multicenter prospective observational study | Q43066576 |
| P433 | issue | 1 | |
| P304 | page(s) | 95 | |
| P577 | publication date | 2016-11-21 | |
| P1433 | published in | BMC Palliative Care | Q15763886 |
| P1476 | title | The association between different opioid doses and the survival of advanced cancer patients receiving palliative care | |
| P478 | volume | 15 | |